# Impact of COVID-19 on the management and outcomes of ureteric stones in

# the UK: a multicentre retrospective study

Matthew H V Byrne<sup>1,2</sup>, Fanourios Georgiades<sup>3,4</sup>, Alexander Light<sup>5</sup>, Catherine E Lovegrove<sup>1,2</sup>, Catherine Dominic<sup>6</sup>, Josephine Rahman<sup>7</sup>, Senthooran Kathiravelupillai<sup>8</sup>, Tobias Klatte<sup>9</sup>, Kasra Saeb-Parsy<sup>4</sup>. Rajeev Kumar<sup>1</sup>, Sarah Howles<sup>1,2</sup>, Grant D Stewart<sup>3,4</sup>, Ben Turney<sup>1,2</sup>, Oliver Wiseman<sup>4</sup> on behalf of the COVID Stones Collaborative\*

# Affiliations:

<sup>1</sup>Nuffield Department of Surgical Sciences, University of Oxford, UK
 <sup>2</sup>Oxford University Hospitals NHS Foundation Trust, UK
 <sup>3</sup>Department of Surgery, University of Cambridge, UK
 <sup>4</sup>Cambridge University Hospitals NHS Foundation Trust, UK
 <sup>5</sup>Department of Surgery and Cancer, Imperial College London, UK
 <sup>6</sup>Barts and the London School of Medicine, Queen Mary University of London, UK
 <sup>7</sup>University of Bristol, UK
 <sup>8</sup>School of Clinical Medicine, University of Cambridge, UK
 <sup>9</sup>Department of Urology, Charité - Universitätsmedizin Berlin, Germany

\*Collaborating authors are listed in Appendix A

# **Corresponding author**

Name: Matthew Byrne Email address: matthew.byrne@nds.ox.ac.uk Full Institution address: Oxford University Hospitals NHS Foundation Trust, UK Institution post code: OX3 7LE Twitter: @mhvbyrne

**Authorship:** MHVB and FG were responsible for conceptualisation. All authors were responsible for writing the first draft and revisions. AL, CD, JR, RK, and Members of the COVID Stone Collaborative were responsible for data collection. MHVB was responsible for data analysis. SH, GDS, BT, and OW were responsible for supervision. BT and OW are the guarantors. All authors have seen and approved the final version.

### Sources of support: None

**Conflicts of interests**: GDS - educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and CMR Surgical; Speaker fees from Pfizer; Trustee The Urology Foundation and Kidney Cancer UK; Travel expenses from Pfizer. OJW: consulting fees: Boston Scientific, EMS, Coloplast, Ambu, Astellas. Speaker fees: Education Boston Scientific, EMS, Coloplast, Ambu. Research grants Coloplast, EMSI; Trustee BAUS, Treasurer BAUS. BT: consulting fees: Boston Scientific; Speaker fees: Boston Scientific, Devicare, BJUI (subeditor); Data safety monitoring / advisory board: Boston Scientific. **Data availability:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Ethical Approval:** We followed NHS Health Research Authority guidance and the study did not require ethical approval. Each participating site obtained local audit approval.

Acknowledgements: None

Study type: Retrospective cohort study

Running Title: COVID Stones study

**Key words:** Urolithiasis, ureteric stone, ureteral stone, COVID-19, patient outcomes, management, conservative management, spontaneous stone passage, ESWL, ureteroscopy, nephrostomy

Number of figures: 1 (+ 0 supplementary) Number of tables: 3 (+ 1 supplementary) Word count: 2079

#### 1 ABSTRACT

2 **Objectives:** To determine if management of ureteric stones in the United Kingdom 3 changed during the COVID-19 pandemic and whether this affected patient 4 outcomes. 5 6 Patients and methods: We conducted a multicentre retrospective study of adults 7 with CT-proven ureteric stone disease at 39 UK hospitals during a pre-pandemic 8 period (23/3/19 to 22/6/19) and a period during the pandemic (the 3-month period 9 after the first SARS-CoV-2 case at individual sites). The primary outcome was 10 success of primary treatment modality, defined as no further treatment required for 11 the index ureteric stone. Our study protocol was published prior to data collection. 12 13 **Results:** A total of 3735 patients were included (pre-pandemic=1956 patients; 14 pandemic=1779 patients). Stone size was similar between groups (p>0.05). During 15 the pandemic, patients had lower hospital admission rates (pre-pandemic=54.0% vs 16 pandemic=46.5%, p<0.001), shorter length of stay (mean=4.1 vs. 3.3 days, p=0.02), 17 and higher rates of use of medical expulsive therapy (17.4% vs. 25.4%, p<0.001). In 18 patients who received interventional management (pre-pandemic n=787 vs. 19 pandemic n=685), rates of ESWL (22.7% vs. 34.1%, p<0.001) and nephrostomy 20 were higher (7.1% vs. 10.5%, p=0.03); and rates of ureteroscopy (57.2% vs. 47.5%, 21 p<0.001), stent insertion (68.4% vs. 54.6%, p<0.001), and general anaesthetic 22 (92.2% vs. 76.2%, p<0.001) were lower. 23 24 There was no difference in success of primary treatment modality between patient

cohorts (pre-pandemic=73.8% vs. pandemic=76.1%, P=0.11), nor when patients

- 26 were stratified by treatment modality or stone size. Rates of operative complications,
- 27 30-day mortality, and readmission and renal function at 6 months did not differ
- 28 between the data collection periods.
- 29
- 30 **Conclusions:** During the COVID-19 pandemic, there were lower admission rates
- 31 and fewer invasive procedures performed. Despite this, there were no differences in
- 32 treatment success or outcomes. Our findings indicate that clinicians can safely adopt
- 33 management strategies developed during the pandemic to treat more patients
- 34 conservatively and in the community.

# 35 INTRODUCTION

Nephrolithiasis is a major clinical and economic health challenge. Up to 20% of men
and 10% of women are affected by stone disease <sup>1,2</sup>. It is responsible for over
85,000 hospital episodes in the UK and costs the UK National Health Service (NHS)
an estimated £190-324 million per year <sup>3</sup>.

40

41	The management of ureteric stones can be conservative, as most stones smaller
42	than 5mm pass spontaneously <sup>4</sup> . However, interventions such as extracorporeal
43	shockwave lithotripsy (ESWL) or ureteroscopic (URS) laser lithotripsy may be
44	required. Untreated stone disease can result in refractory pain, sepsis, renal failure,
45	and death $^{5}$ . The UK National Institute for Health and Care Excellence (NICE)
46	guidelines published in 2019 recommend that adults with ureteric stones measuring
47	less than 10mm should be treated with ESWL and URS is recommended as a
48	second line alternative. For ureteric stones measuring between 10 and 20mm, URS
49	should be offered as first line treatment, and ESWL can be considered if local
50	facilities will allow stone clearance to be achieved within 4 weeks <sup>6</sup> .
51	
52	In March 2020, COVID-19 was declared a pandemic by the World Health
53	Organisation (WHO), and measures were introduced across the world to mitigate the
54	spread of infection <sup>7</sup> . There was worldwide disruption to healthcare provision,
55	including increased pressures on healthcare services and the cancellation of elective
56	procedures <sup>8</sup> . The multicentre, international COVIDSurg study demonstrated that
57	perioperative infection with the SARS-CoV-2 virus was associated with an
58	unadjusted 30-day mortality of 23.8% $^{9}$ . In light of this, and as a result of reduced
59	access to operating theatres, recommendations were made to favour non-operative

management strategies<sup>8,10–12</sup>. Furthermore, during the peak of the pandemic in the 60 61 UK, non-COVID-19 related Emergency Department attendances fell dramatically as 62 patients delayed or avoided presentation to hospital due to fear of infection <sup>13</sup>. 63 64 The existing body of literature around COVID-19 and endourology discusses 65 alterations required of clinical care to accommodate the widespread disruption to 66 healthcare services due to COVID-19. However, these articles were written at the 67 start of the COVID-19 pandemic and do not discuss whether these suggested 68 changes to treatment algorithms manifested during the pandemic or what their 69 impact on outcomes were <sup>11,12,14</sup>. 70 71 We hypothesised that during COVID-19 there were delays in patient presentation 72 resulting in higher rates of AKI and sepsis and that non-invasive management 73 options such as observation, ESWL, and alternatives to general anaesthesia were 74 used more frequently, resulting in higher rates of failed index management and 75 subsequent change in treatment modality and/or re-presentation to hospital. We 76 sought to test this hypothesis by undertaking a multicentre, retrospective study to 77 determine how management of ureteric stones changed during the COVID-19 78 pandemic in the United Kingdom and define how changes in management affected 79 patient outcomes.

# 80 METHODS

#### 81 Study design

82 We conducted a multicentre, retrospective cohort study of the management and

83 outcomes of patients presenting with ureteric stones before and during the COVID-

84 19 pandemic at 39 hospitals in the United Kingdom.

85

86 Our protocol was published prior to data collection <sup>15</sup>. We followed principles of the

87 trainee-led collaborative research model <sup>16</sup>, coordinated by the COVID Stones

88 Collaborative; and the STROBE (STrengthening the Reporting of OBservational

89 studies in Epidemiology) guidelines <sup>17</sup> (Appendix B). NHS Health Research Authority

90 guidance was followed, and each participating site obtained local audit approval.

91

92 Patients aged ≥18 years with ureteric stone disease confirmed on contrast or non-

93 contrast computed tomography (CT) imaging were identified via retrospective review

94 of all abdominal CT scans undertaken during relevant data collection periods.

95 Patients with non-ureteric stone disease were excluded.

#### 96 Data collection

97 Data was collected during two time periods: a pre-pandemic period from 23/3/19 to

98 22/6/19; and a period during the pandemic, which was defined as the 3-month period

99 after the first SARS-CoV-2 case at each individual site. This time point was

approximately equivalent to the start of the first UK lockdown due to Covid-19 on

101 23/3/20. Data was collected by local collaborators, and entered and stored on the

102 Research Electronic Data Capture (REDCap) server managed and hosted by the

103 University of Oxford, UK <sup>18,19</sup>. Data collected included demographics, management
104 and outcomes at 6 months follow-up.

#### 105 Outcomes

- 106 Our primary objective was to assess success of primary treatment modality, defined
- 107 as no additional treatment required for the index ureteric stone. Our secondary
- 108 objectives were to assess rates of non-operative management, ESWL, stent
- 109 insertion, ureteroscopy, and nephrostomy insertion; type of anaesthesia for operative
- 110 management options; operative complications; hospital admission and length of stay;
- 111 30-day and 6-month mortality; readmission, and impact of stone on renal function.

### 112 Statistical analysis

- 113 Statistical analysis was performed using R (version 4.1.0)<sup>20</sup>. Patients in the pre-
- 114 pandemic cohort were compared to patients in the pandemic cohort. Two-sided
- 115 unpaired t-tests, and Chi-squared tests were used to analyse the data. Data is
- 116 presented as mean ± standard deviation (SD) or as raw number and percentage. A
- 117 p-value <0.05 was deemed significant.

#### 118 **RESULTS**

# 119 **Demographics**

- 120 Data were collected from a total of 3735 patients from 39 centres. In the pre-
- 121 pandemic period data were entered for 1956 patients, and in pandemic period data
- 122 was entered for 1779 patients. Baseline patient characteristics were broadly similar
- 123 (Table 1). Although, there was a significant difference in age between cohorts, the
- 124 median age group for both cohorts was 50-59 years.
- 125
- 126 Stone site and size were similar between cohorts (Table 1). Unexpectedly, patients

127 from the pre-pandemic cohort were reported to have significantly higher rates of

128 active infection and acute kidney injury on admission, and fever at any point during

- 129 index admission. However, mean C-reactive protein, white cell count, positive
- 130 microbiology cultures (urine or blood), and creatinine were not significantly different

131 (Table 1).

### 132 Management

- 133 Overall, patients in the pandemic period had significantly lower rates of admission to
- hospital (pre-pandemic 54.0% vs. pandemic 46.5%, p<0.001) and shorter length of
- 135 stay in hospital (mean length of stay in days, pre-pandemic=4.1 (SD=8.0) vs.
- 136 pandemic=3.3 (SD=5.9), p=0.02) compared to the pre-pandemic period. The use of
- 137 alpha blockers was significantly higher during the pandemic (pre-pandemic=17.4%
- 138 vs. pandemic=25.4%, p<0.001). Despite the higher rates of active infection and
- 139 fever, antibiotic usage was similar between cohorts (Table 2).

# 140 Interventional management

141	There were no differences in rates of interventional management between the
142	cohorts (pre-pandemic, n=787 [40.2%] vs. pandemic, n=685 [38.5%], p=0.30), or
143	ASA grade (p=0.50) and WHO/ECOG Performance status (p=0.21) in patients who
144	received operative management (Table S1). However, there were significantly higher
145	rates of ESWL and nephrostomy insertion, and significantly lower rates of general
146	anaesthetic, ureteroscopy and stent insertion during the pandemic compared to pre-
147	pandemic (Figure 1, Table 2). During the pandemic, planned interventions were
148	delayed due to COVID-19 status in 63 out of 1580 patients (4.0%).

### 149 Outcomes

- 150 30-day outcomes
- 151 The 30-day operative complication rate among those who received operative
- 152 management was similar between the pre-pandemic and pandemic cohort (Table 2),
- 153 as was the 30-day mortality rate (any cause) across the whole of each cohort (pre-
- 154 pandemic=8 of 1793 [0.5%] vs. pandemic=9 of 1640 [0.6%], p=0.85).
- 155 6-month outcomes
- 156 The success rate of primary treatment (i.e. no further treatment required for the index
- 157 stone after primary treatment modality) was similar between cohorts (pre-
- 158 pandemic=73.8% vs. pandemic=76.1%, p=0.11). There was no significant difference
- 159 in success of primary treatment modality when stratified by treatment modality or
- 160 stone size.

- 162 In patients who did require further intervention, the rates of ESWL, ureteroscopy,
- 163 retrograde stent insertion, and nephrostomy were similar between each cohort
- 164 (Table 3).
- 165
- 166 The mean number of unplanned admissions (pre-pandemic=0.17 (SD=0.52) vs.
- 167 pandemic=0.18 (SD=0.50), p=0.83), mean creatinine (pre-pandemic=87.3 (SD=36.9)
- 168 vs. pandemic=89.4 (SD=51.9) µmol/L, p=0.31), and chronic kidney disease stage 1
- to 5 (pre-pandemic=17.1% vs. pandemic=17.9%, p=0.99) were similar between
- 170 cohorts. There was a higher mortality rate in the pre-pandemic cohort group (pre-
- 171 pandemic=40 of 1830 [2.1%] vs. pandemic=18 of 1700 [1.1%], p=0.01).

# 172 DISCUSSION

173	In response to the COVID-19 pandemic, strategies to prioritise and triage patients
174	with urological pathology were developed <sup>12</sup> . These included conservative treatment
175	whenever possible <sup>12</sup> , and use of local-anaesthesia to minimise ventilator use and
176	reduce risk of COVID-19 exposure <sup>11,12,14</sup> . If operative management was deemed
177	necessary, recommendations were made to select patients according to surgical
178	priority using patient factors (symptoms, comorbidities, and renal tract abnormalities)
179	and stone factors (obstruction, infection, and conservative management failure) <sup>11,12</sup> .
180	In cases where there was an infected, obstructed system, multiple sources
181	recommended insertion of a ureteric stent under local anaesthetic as first line
182	treatment, with nephrostomy as second line option <sup>12,14</sup> .
183	
184	In this study, we demonstrate that the management of ureteric stones changed
184 185	In this study, we demonstrate that the management of ureteric stones changed across the UK during at the onset of the COVID-19 pandemic, with fewer invasive
185	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive
185 186	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We
185 186 187	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We also found that rates of nephrostomy were higher, despite lower rates of AKI and
185 186 187 188	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We also found that rates of nephrostomy were higher, despite lower rates of AKI and
185 186 187 188 189	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We also found that rates of nephrostomy were higher, despite lower rates of AKI and active infection.
185 186 187 188 189 190	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We also found that rates of nephrostomy were higher, despite lower rates of AKI and active infection.
185 186 187 188 189 190 191	across the UK during at the onset of the COVID-19 pandemic, with fewer invasive procedures and increased rates of ESWL and medical expulsive management. We also found that rates of nephrostomy were higher, despite lower rates of AKI and active infection. Other studies have reported a decrease in urological presentations during the COVID-19 pandemic <sup>21–24</sup> We therefore predicted that during the pandemic patients

- 195 delay their presentation long enough to impact their clinical condition. These findings
- 196 contrast with other urolithiasis datasets. Castellani et al. compared ureteric stone

197	disease outcomes of 298 patients prior to the pandemic with 218 patients during the
198	pandemic, reporting reduced admissions and higher rates of infected-obstructed
199	systems, hospitalisation, and intervention during the COVID-19 pandemic <sup>25</sup> .
200	Furthermore, Flammia et al. found that serum creatinine was significantly higher in
201	36 patients with urinary stone emergencies during the pandemic compared to 44
202	patients with urinary stone emergencies prior to the pandemic, which the authors
203	posited was due to delayed presentation <sup>26</sup> . Similarly, Gul et al. demonstrated an
204	increase in creatinine, white cell count, hospital admissions, antibiotic treatment, and
205	emergency nephrostomy insertion in 35 patients with urolithiasis during the
206	pandemic compared to 114 patients with urolithiasis prior to the pandemic <sup>27</sup> .
207	
208	Our findings are consistent with those reported by Anderson et al. and Nourian et al.
209	who identified no difference in markers of infection or AKI between pre-pandemic
210	and post-pandemic cohorts of patients presenting with urolithiasis <sup>28, 29</sup> . Our study
211	represents the largest cohort to date investigating ureteric stone outcomes during the
212	pandemic, has a multicentre design and had a pre-defined protocol. Thus, we predict
213	our findings are representative of true outcomes in the UK during the COVID-19
214	pandemic.
215	
216	Steinberg et al. suggested that we can use the COVID-19 pandemic as an
217	opportunity to reassess ureteric stone management strategies, and establish
218	whether conservative management strategies have been under-used <sup>30</sup> . Our study is
219	the first to evaluate the impact of changes in the management of ureteric stones
220	during the COVID-19 pandemic on patient outcomes at 6 month follow up <sup>26,28,29,31,32</sup> .
221	We demonstrate that increased use of conservative management strategies did not

222	have a detrimental effect on primary treatment success or patient outcomes at 6-
223	month follow up. Our data supports increased use of less-invasive options
224	recommended by NICE guidance including watchful waiting with medical expulsive
225	therapy and ESWL as first line – there was an approximately 10% shift from URS to
226	ESWL during the pandemic with non-inferior outcomes. Our data also support a
227	reduction in admission rates and earlier discharge. It is unclear whether these
228	changes will revert once the pandemic stabilises and patient backlog is tackled or if
229	practice will change permanently. Evidence such as this should drive a more
230	permanent change to less-invasive management, as the change in practice during
231	the pandemic has shown that this is safe and as effective.
232	
233	This study is the first of its kind to be conducted across multiple sites with 6-month
234	follow-up. However, the study is limited by its retrospective design, and missing data.
235	Our study was conducted across 39 centres and the number of cases entered by
236	each centre varied considerably. This may be due to differences in local patient
237	populations, however, it may be that not all patients within each time period were
238	captured. This increases the risk of selection bias within our study and therefore no
239	comment can be made on whether there was a change in the number of
240	presentations with ureteric stone disease during each time period.

# 241 CONCLUSIONS

- As a result of the COVID-19 pandemic patients in the UK with ureteric stones were
- 243 less likely to be treated invasively and more likely to be managed without admission.
- 244 However, this change in practice did not result in inferior outcomes for patients. The
- 245 pandemic has given the urological community an opportunity to re-evaluate
- 246 management of ureteric stones; our findings indicate that a greater proportion of
- 247 ureteric stones can be managed safely and effectively with non-invasive ambulatory
- 248 options.

#### 249 **REFERENCES**

- 250 1. Heers H, Turney BW. Trends in urological stone disease: a 5-year update of
- hospital episode statistics. *BJU Int.* 2016;118(5):785-789.
- 252 doi:10.1111/bju.13520
- 253 2. Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of Kidney Stones in
- 254 the United States. *Eur Urol.* 2012;62(1):160-165.
- 255 doi:10.1016/j.eururo.2012.03.052
- 256 3. Geraghty RM, Cook P, Walker V, Somani BK. Evaluation of the economic
- burden of kidney stone disease in the UK: a retrospective cohort study with a
- 258 mean follow-up of 19 years. *BJU Int*. 2020;125(4):586-594.
- 259 doi:10.1111/bju.14991
- 260 4. Shah TT, Gao C, Peters M, et al. Factors associated with spontaneous stone
- 261 passage in a contemporary cohort of patients presenting with acute ureteric
- 262 colic: results from the Multi-centre cohort study evaluating the role of
- 263 Inflammatory Markers In patients presenting with acute ureteric. *BJU Int.*
- 264 2019;124(3):504-513. doi:10.1111/bju.14777
- 265 5. PEARLE MS, PIERCE HL, MILLER GL, et al. OPTIMAL METHOD OF
- 266 URGENT DECOMPRESSION OF THE COLLECTING SYSTEM FOR
- 267 OBSTRUCTION AND INFECTION DUE TO URETERAL CALCULI. J Urol.
- 268 1998;160(4):1260-1264. doi:10.1016/S0022-5347(01)62511-4
- 269 6. NICE guideline NG118: Renal and ureteric stones: Assessment and270 management.
- 271 7. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed.
- 272 2020;91(1):157-160. doi:10.23750/abm.v91i1.9397
- 273 8. COVIDSurg Collaborative . Elective surgery cancellations due to the COVID-

274		19 pandemic: global predictive modelling to inform surgical recovery plans. Br
275		<i>J Surg</i> . June 2020. doi:10.1002/bjs.11746
276	9.	Nepogodiev D, Bhangu A, Glasbey JC, et al. Mortality and pulmonary
277		complications in patients undergoing surgery with perioperative SARS-CoV-2
278		infection: an international cohort study. Lancet. 2020;396(10243):27-38.
279		doi:10.1016/S0140-6736(20)31182-X
280	10.	Royal College of Surgeons of England. Updated Inter-collegiate General
281		Surgery Guidance on COVID-19. London: Royal College of Surgeons of
282		England.
283	11.	Metzler IS, Sorensen MD, Sweet RM, Harper JD. Stone Care Triage During
284		COVID-19 at the University of Washington. J Endourol. 2020;34(5):539-540.
285		doi:10.1089/end.2020.29080.ism
286	12.	Proietti S, Gaboardi F, Giusti G. Endourological Stone Management in the Era
287		of the COVID-19. Eur Urol. 2020;78(2):131-133.
288		doi:10.1016/j.eururo.2020.03.042
289	13.	Thornton J. Covid-19: A&E visits in England fall by 25% in week after
290		lockdown. BMJ. April 2020:m1401. doi:10.1136/bmj.m1401
291	14.	Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of
292		Urologic Surgeries During the COVID-19 Pandemic. Eur Urol. 2020;77(6):663-
293		666. doi:10.1016/j.eururo.2020.03.027
294	15.	Georgiades F, Byrne MH, Lovegrove CE, et al. The COVID Stones
295		Collaborative: How has the Management of Ureteric Stones Changed During
296		and After the COVID-19 Pandemic? Rationale and Study Protocol. $J$
297		Endoluminal Endourol. 2020;3(3):e22-e28. doi:10.22374/JELEU.V3I3.96
298	16.	Blencowe N, Glasbey J, Heywood N, et al. Recognising contributions to work

- in research collaboratives: Guidelines for standardising reporting of authorship
- in collaborative research. *Int J Surg.* 2018;52:355-360.
- 301 doi:10.1016/J.IJSU.2017.12.019
- 302 17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
- 303 JP. The Strengthening the Reporting of Observational Studies in Epidemiology
- 304 (STROBE) statement: guidelines for reporting observational studies. *Lancet*.
- 305 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
- 306 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
- 307 electronic data capture (REDCap)—A metadata-driven methodology and
- 308 workflow process for providing translational research informatics support. J

309 Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010

- 310 19. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an
- 311 international community of software platform partners. *J Biomed Inform*.
- 312 2019;95:103208. doi:10.1016/j.jbi.2019.103208
- 313 20. R Core Team. R: A language and environment for statistical computing. 2017.
  314 https://www.r-project.org/.
- 315 21. Madanelo M, Ferreira C, Nunes-Carneiro D, et al. The impact of the
- 316 coronavirus disease 2019 pandemic on the utilisation of emergency urological
- 317 services. *BJU Int*. 2020;126(2):256-258. doi:10.1111/BJU.15109
- 318 22. Motterle G, Morlacco A, lafrate M, et al. The impact of COVID-19 pandemic on
- 319 urological emergencies: a single-center experience. *World J Urol.* 2021;39(6).
- 320 doi:10.1007/S00345-020-03264-2
- 321 23. Porreca A, Colicchia M, D'Agostino D, et al. Urology in the Time of
- 322 Coronavirus: Reduced Access to Urgent and Emergent Urological Care during
- 323 the Coronavirus Disease 2019 Outbreak in Italy. Urol Int. 2020;104(7-8):631-


#### 324 636. doi:10.1159/000508512

- 325 24. Korkes F, Smaidi K, Salles MP, Neto ACL, Heilberg IP, Glina S. COVID-19:
- 326 The impact on urolithiasis treatment in Brazil. Int Braz J Urol. 2022;48(1):101-
- 327 109. doi:10.1590/S1677-5538.IBJU.2021.0405
- 328 25. Castellani D, Ragonese M, Di Rosa M, et al. An Italian multicenter analysis of
- 329 emergency admissions and treatment of upper tract urolithiasis during the
- 330 lockdown and reopening phases of the COVID-19 pandemic: Are we ready for
- a second wave of the outbreak? *Int J Urol*. 2021;28(9):950.
- 332 doi:10.1111/IJU.14612
- 333 26. Flammia S, Salciccia S, Tufano A, Busetto GM, Ricciuti GP, Sciarra A. How
- 334 urinary stone emergencies changed in the time of COVID-19? *Urolithiasis*.
- 335 2020;48(5):467-469. doi:10.1007/s00240-020-01198-3
- 336 27. Gul M, Kaynar M, Yildiz M, et al. The Increased Risk of Complicated Ureteral
- 337 Stones in the Era of COVID-19 Pandemic. *J Endourol.* 2020;34(8):882-886.
- 338 doi:10.1089/end.2020.0658
- 339 28. Anderson S, McNicholas D, Murphy C, et al. The impact of COVID-19 on acute
- 340 urinary stone presentations: a single-centre experience. *Ir J Med Sci*.
- 341 2022;191(1):45-49. doi:10.1007/S11845-021-02562-X
- 342 29. Nourian A, Uppaluri C, Chen M, Ghiraldi EM, Friedlander JI. Comparison of
- 343 Management and Outcomes of Symptomatic Urolithiasis During the COVID-19
- 344 Pandemic to a Comparative Cohort. *Urology*. 2022.
- 345 doi:10.1016/J.UROLOGY.2022.01.019
- 346 30. Steinberg RL, Johnson BA, Antonelli J, Pearle MS. Urolithiasis in the COVID
- 347 Era: An Opportunity to Reassess Management Strategies. *Eur Urol.*
- 348 2020;78(6):777. doi:10.1016/J.EURURO.2020.07.019

- 349 31. Liu Z, Man L. Impacts of the COVID-19 outbreak on visits and treatments for
- 350 patients with ureteral stones in a general hospital emergency department. *Urol*
- 351 J. 2021;88(3):232-236. doi:10.1177/0391560320985659
- 352 32. Gökce Mİ, Yin S, Sönmez MG, et al. How does the COVID-19 pandemic affect
- 353 the preoperative evaluation and anesthesia applied for urinary stones? EULIS
- 354 eCORE–IAU multicenter collaborative cohort study. *Urolithiasis*.
- 355 2020;48(4):345-351. doi:10.1007/s00240-020-01193-8

# 357 FIGURE CAPTIONS

358



359 Figure 1: Change in interventional management during the pandemic

# 360 TABLE CAPTIONS

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	p- value
Age group			0.02
18-19 years	11 (0.6%)	17 (1.0%)	
20-29 years	198 (10.1%)	164 (9.2%)	
30-39 years	340 (17.4%)	346 (19.4%)	
40-49 years	361 (18.5%)	359 (20.2%)	
50-59 years	409 (20.9%)	405 (22.8%)	
60-69 years	336 (17.2%)	267 (15.0%)	
70-79 years	210 (10.7%)	149 (8.4%)	
80+ years	90 (4.6%)	72 (4.1%)	
Gender			0.823
Female	576 (29.4%)	517 (29.1%)	
Male	1380 (70.6%)	1262 (70.9%)	
ВМІ			
Mean (SD)	28.8 (6.3)	29.6 (7.4)	0.074
Median [IQR]	28.0 [24.4-32.1]	28.7 [24.7-32.9]	
Non-urological comorbidities			0.075
Yes	538 (36.2%)	453 (32.9%)	
No	950 (63.8%)	923 (67.1%)	
Urological comorbidities			0.662
Yes	56 (3.8%)	46 (3.4%)	
No	1429 (96.2%)	1309 (96.6%)	
Ureteric stone location?			0.52
Left	1014 (51.8%)	929 (52.2%)	
Right	873 (44.6%)	799 (44.9%)	
Bilateral	69 (3.53%)	51 (2.87%)	
Maximum stone size (mm)			0.687
≤5	1026 (57.5%)	926 (56.9%)	
6-10	633 (35.5%)	598 (36.8%)	
11-19	108 (6.1%)	85 (5.2%)	
≥20	18 (1.0%)	17 (1.1%)	
Active infection at time of presentation			0.032
Yes	258 (13.2%)	193 (10.8%)	
No	1697 (86.8%)	1586 (89.2%)	
Fever (Temperature >38 degree C) at any stage in index admission			0.031
Yes	151 (9.3%)	107 (7.1%)	
No	1482 (90.8%)	1406 (92.9%)	
Admission blood tests CRP (mg/L)			0.562
Mean (SD)	27.7 (64.6)	26.4 (68.7)	
Median [IQR]	4.0 [1.0-17.0]	3.0 [1.0-13.0]	
Admission blood tests WCC (x10^9/L)			0.725

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	p- value
Mean (SD)	11.0 (6.2)	11.0 (4.2)	
Median [IQR]	10.3 [8.1-12.9]	10.7 [8.1-13.1]	
Positive blood culture			0.749
Yes	51 (38.1%)	41 (41.0%)	
No	83 (61.9%)	59 (59.0%)	
Positive urine culture (>10^5 cfu)			0.796
Yes	97 (21.8%)	78 (20.9%)	
No	347 (78.2%)	296 (79.1%)	
Admission blood tests Creatinine (umol/L)			0.765
Mean (SD)	105 (70.8)	106 (75.9)	
Median [IQR]	94.0 [77.0-113.0]	93.0 [78.0-113.0]	
AKI			0.041
Yes	340 (21.9%)	290 (18.9%)	
No	1211 (78.1%)	1245 (81.1%)	
AKI Grade (KGIDO)			
Grade 1	226 (74.1%)	202 (74.8%)	
Grade 2	55 (18.0%)	44 (16.3%)	
Grade 3	24 (7.9%)	24 (8.9%)	

361 Table 1: baseline characteristics between the pre-pandemic patient cohort and the

362 pandemic patient cohort. AKI = acute kidney injury CFU = colony forming units; CRP

363 = C reactive protein; IQR = interquartile range; SD = standard deviation; WCC =

364 white cell count.

	Pre-pandemic period	Pandemic period	P-value
	(N=1956)	(N=1779)	i -vaiue
Admitted to hospital?			<0.001
Yes	1057 (54.0%)	827 (46.5%)	
No	899 (46.0%)	952 (53.5%)	
Length of stay (days)			0.021
Mean (SD)	4.08 (8.04)	3.29 (5.94)	
Alpha blocker			<0.001
Yes	316 (17.4%)	414 (25.4%)	
No	1501 (82.6%)	1219 (74.6%)	
Antibiotics			
Yes-Oral	171 (8.74%)	148 (8.32%)	0.251
Yes-IV	304 (15.5%)	245 (13.8%)	
No	1481 (75.7%)	1386 (77.9%)	
Interventional management			0.295
Yes	787 (40.2%)	685 (38.5%)	
No	1169 (59.8%)	1094 (61.5%)	
	Pre-pandemic period	Pandemic period	
	(N=787)	(N=685)	P-value
Anaesthetic			<0.001
General	390 (92.2%)	173 (76.2%)	
Non-general	33 (7.80%)	54 (23.8%)	
ESWL for index stone			<0.001
Yes	179 (22.7%)	233 (34.1%)	
No	608 (77.3%)	451 (65.9%)	

Ureteroscopy for index stone			<0.001
Yes	450 (57.2%)	325 (47.5%)	
No	337 (42.8%)	359 (52.5%)	
Stent insertion for index stone (alone or as par	t of Ureteroscopy)		<0.001
Yes	538 (68.4%)	374 (54.6%)	
No	249 (31.6%)	311 (45.4%)	
Emergency nephrostomy insertion for index st	one		0.027
Yes	56 (7.1%)	72 (10.5%)	
No	731 (92.9%)	613 (89.5%)	
Operative complication			0.616
Yes	87 (11.5%)	68 (10.5%)	
No	671 (88.5%)	580 (89.5%)	
30-day highest Clavien-Dindo grade			
None	671 (88.5%)	580 (89.5%)	
1	44 (5.8%)	28 (4.3%)	
II	29 (3.8%)	15 (2.3%)	
III-A	1 (0.1%)	8 (1.2%)	
III-B	9 (1.2%)	12 (1.9%)	
IV-A	2 (0.3%)	0 (0.0%)	
IV-B	1 (0.1%)	2 (0.3%)	
V (death)	1 (0.1%)	3 (0.5%)	

# 367 Table 2: Management and complications

### 369

	Pre-pandemic period	Pandemic period	P-value
	(N=1956)	(N=1779)	
Primary treatn	nent success		0.113
Yes	1379 (73.8%)	1308 (76.1%)	
No	490 (26.2%)	410 (23.9%)	
Unplanned rea	admission for ureter	ric stone disease	0.826
Mean (SD)	0.173 (0.520)	0.176 (0.500)	
Creatinine (un	nol/L)		0.305
Mean (SD)	87.3 (36.9)	89.4 (51.9)	
СКД			0.989
Yes	230 (17.2%)	213 (17.1%)	
No	1111 (82.8%)	1036 (82.9%)	
Death			0.014
Yes	40 (2.14%)	18 (1.05%)	
No	1830 (97.9%)	1700 (99.0%)	
Additional interventions			
ESWL			0.231
Yes	87 (4.9%)	95 (5.8%)	
No	1689 (95.1%)	1519 (94.1%)	
Ureteroscopy	+/- Laser lithotripsy	+/- Stent insertion	0.072
Yes	358 (19.5%)	288 (17.1%)	

No 1481 (80.5%) 1400 (82.9%)

#### Stent insertion retrograde

Yes	84 (4.8%)	69 (4.3%)
No	1685 (95.3%)	1524 (95.7%)

0.62

Nephrostomy	insertion		0.782
Yes	17 (1.0%)	13 (0.8%)	
No	1767 (99.0%)	1602 (99.2%)	

370

371 Table 3: Outcomes and additional operative management required at 6 months

372 follow-up.

# 373 SUPPLEMENTARY TABLES

	Pre-pandemic period	Pandemic period	P-value
	(N=787)	(N=685)	
ASA grade			
1. A normal healthy patient	219 (42.0%)	134 (43.4%)	0.498
2. A patient with mild systemic disease	199 (38.1%)	125 (40.5%)	
3. A patient with severe systemic disease	89 (17.0%)	45 (14.6%)	
4. A patient with severe systemic disease that is a	15 (2.87%)	5 (1.62%)	
constant threat to life	13 (2.0776)	5 (1.0270)	
WHO/ECOG Performance status			
Fully active, able to carry on all pre-disease activities	326 (73.1%)	211 (75.9%)	0.214
Restricted in physical strenuous activity, able to perform	87 (19.5%)	39 (14.0%)	
light work	67 (19.576)	39 (14.076)	
Ambulatory and capable of all self-care, unable to work	18 (4.04%)	15 (5.40%)	
Capable of limited self-care only	11 (2.47%)	7 (2.52%)	
Completely disabled. Confined to bed or chair	4 (0.897%)	6 (2.16%)	

374 Table S1: ASA Grade and WHO/ECOG Performance status